Postmarketing safety surveillance of dexamethasone intravitreal implant in the treatment of visual impairment due to diabetic macular edema in India

Postmarketing safety surveillance of dexamethasone intravitreal implant in the treatment of visual impairment due to diabetic macular edema in India

Abstract Background Diabetic macular edema (DME) is the most common cause of vision loss in diabetic patients. As India has the second largest population of diabetic patients worldwide, availability of various treatment options for DME is essential. This postmarketing surveillance study was conducte...

Full description

Bibliographic Details
Main Authors: Unnikrishnan Nair, Vishali Gupta, Mohita Sharma, Shrinivas Joshi, Aditya Sudhalkar, Undraa Altangerel, Yan Bai, for the India Ozurdex Postmarketing Surveillance Study Group
Format: Article
Language:English
Published: BMC 2020-10-01
Series:BMC Ophthalmology
Subjects:
Corticosteroid
Dexamethasone
Diabetic macular edema
Postmarketing
Safety profile
Online Access:http://link.springer.com/article/10.1186/s12886-020-01630-7

Internet

http://link.springer.com/article/10.1186/s12886-020-01630-7

Similar Items